Literature DB >> 17463073

Pooled historical MRI data as a basis for research in multiple sclerosis--a statistical evaluation.

S Schach1, M Scholz, J S Wolinsky, L Kappos.   

Abstract

Pooled data from placebo groups of different trials can serve as historical control for ongoing or future therapeutic studies and as a reference for power calculations. In order to assess their usefulness for this purpose, we investigated the degree of heterogeneity of placebo arm data from 14 controlled studies included in the database of the Sylvia Lawry Centre for Multiple Sclerosis Research. Since different criteria for the inclusion/exclusion of patients were used in these studies, an attempt was made to adjust the distribution of magnetic resonance imaging (MRI) measures for the differences in the study populations. The analyses showed that, even after adjustment, significant differences remained. This heterogeneity does not reduce the usefulness of the database for statistical analysis of inter-relationships between variables, provided that it is explicitly taken into account as a stratification factor. However, care must be taken when trying to compare the results of a newly treated group with the patients of this pool. Heterogeneity in some MRI variables was greatly reduced when only studies from the same image analysis centre were compared.

Entities:  

Mesh:

Year:  2007        PMID: 17463073     DOI: 10.1177/1352458506069537

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  5 in total

1.  MRI--the perfect surrogate marker for multiple sclerosis?

Authors:  Frederik Barkhof; Massimo Filippi
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

2.  Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses.

Authors:  J Petkau; S C Reingold; U Held; G R Cutter; T R Fleming; M D Hughes; D H Miller; H F McFarland; J S Wolinsky
Journal:  Mult Scler       Date:  2008-06-05       Impact factor: 6.312

3.  Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies.

Authors:  Kunio Nakamura; Oksana Mokliatchouk; Douglas L Arnold; Tarek A Yousry; Ludwig Kappos; Nancy Richert; Katherine Ayling-Rouse; Catherine Miller; Elizabeth Fisher
Journal:  Front Neurol       Date:  2022-03-18       Impact factor: 4.003

4.  Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.

Authors:  Frank Dahlke; Douglas L Arnold; Piet Aarden; Habib Ganjgahi; Dieter A Häring; Jelena Čuklina; Thomas E Nichols; Stephen Gardiner; Robert Bermel; Heinz Wiendl
Journal:  Mult Scler       Date:  2021-01-28       Impact factor: 6.312

5.  How patients with multiple sclerosis acquire disability.

Authors:  Fred D Lublin; Dieter A Häring; Habib Ganjgahi; Alex Ocampo; Farhad Hatami; Jelena Čuklina; Piet Aarden; Frank Dahlke; Douglas L Arnold; Heinz Wiendl; Tanuja Chitnis; Thomas E Nichols; Bernd C Kieseier; Robert A Bermel
Journal:  Brain       Date:  2022-09-14       Impact factor: 15.255

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.